` 4502 (Takeda Pharmaceutical Co Ltd) vs Nikkei 225 Comparison - Alpha Spread

4502
vs
Nikkei 225

Over the past 12 months, has outperformed Nikkei 225, delivering a return of 1% compared to the Nikkei 225's 4% drop.

Stocks Performance
4502 vs Nikkei 225

Loading
4502
Nikkei 225
Add Stock

Performance Gap
4502 vs Nikkei 225

Loading
4502
Nikkei 225
Difference
www.alphaspread.com

Performance By Year
4502 vs Nikkei 225

Loading
4502
Nikkei 225
Add Stock

Competitors Performance
Takeda Pharmaceutical Co Ltd vs Peers

Nikkei 225
4502
LLY
JNJ
NOVO B
ROG
Add Stock

Takeda Pharmaceutical Co Ltd
Glance View

Market Cap
6.7T JPY
Industry
Pharmaceuticals

In the ever-evolving landscape of global pharmaceuticals, Takeda Pharmaceutical Co Ltd. stands as a robust and adaptive entity, blending a rich heritage with bold innovation. Originating from Japan, Takeda's journey began over two centuries ago, carving its niche by focusing on value-driven and research-led approaches in the pharmaceutical industry. With its headquarters in Tokyo, the company has fortified its position as one of the global leaders, largely due to its emphasis on research and development that spans across cutting-edge areas such as oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies. This innovation-centric strategy is not just a nod to the future, but a crucial component that allows Takeda to address pressing health challenges worldwide, continually expanding its pipeline with transformative therapies. Takeda's commercial model revolves around its diverse therapeutic portfolio and strategic collaborations, which are instrumental in capturing growth across various markets. By leveraging its scientific expertise and expanding technological capabilities, the company advances its core business segments while integrating augmented biotechnology solutions through strategic acquisitions and partnerships. The absorption of Shire, a prominent biotechnology firm, stands as a hallmark of Takeda's commitment to enhancing its presence in rare diseases and plasma-derived therapies, thereby widening its global footprint. This focus not only fuels revenue generation from innovative products but also ensures a multidimensional approach to market entry across pivotal regions. Through balancing its inventive drive with operational efficiency, Takeda efficiently monetizes its products, securing its status as a formidable player in the pharmaceutical domain.

Intrinsic Value
4 908.8 JPY
Undervaluation 13%
Intrinsic Value
Price
Back to Top